{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:45:59Z","timestamp":1775529959394,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,6]],"date-time":"2015-09-06T00:00:00Z","timestamp":1441497600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>The incidence of <jats:italic>Neisseria gonorrhoeae<\/jats:italic> infections in the United States has grown over the past decade. The most recent data provided by the Centers for Disease Control and Prevention (<jats:styled-content style=\"fixed-case\">CDC<\/jats:styled-content>) indicate that reported cases have increased by almost 10% over the last 5\u00a0years. In conjunction with this rise, the presence of multidrug\u2010resistant strains of <jats:italic>N.\u00a0gonorrhoeae<\/jats:italic> has also emerged. The 2015 <jats:styled-content style=\"fixed-case\">CDC<\/jats:styled-content> guidelines recommend dual therapy with intramuscular ceftriaxone and oral azithromycin as first\u2010line treatment, although components of this regimen are met with a high level of resistance. Although ceftriaxone resistance has not yet been reported in the United States, it is only a matter of time before such isolates are detected, thus ushering in a new era of difficult\u2010to\u2010manage uncomplicated gonococcal infection. The potential public health crisis and patient\u2010associated sequelae (e.g., pelvic inflammatory disease, epididymitis, and human immunodeficiency virus infection) linked with untreatable gonorrhea are cause for great concern. To try to stem this tide, a number of new agents targeted against <jats:italic>N.\u00a0gonorrhoeae<\/jats:italic> are being investigated in clinical trials. In this article, we review the various agents, both currently available and under clinical investigation, and provide recommendations for the management of gonococcal infections.<\/jats:p>","DOI":"10.1002\/phar.1627","type":"journal-article","created":{"date-parts":[[2015,9,6]],"date-time":"2015-09-06T22:58:44Z","timestamp":1441580324000},"page":"856-868","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Update on Treatment Options for Gonococcal Infections"],"prefix":"10.1002","volume":"35","author":[{"given":"Jason W.","family":"Lancaster","sequence":"first","affiliation":[{"name":"School of Pharmacy Northeastern University Boston Massachusetts"},{"name":"Department of Pharmacy Lahey Hospital &amp; Medical Center Burlington Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica V.","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Beth Israel Deaconess Medical Center Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Mandal","sequence":"additional","affiliation":[{"name":"School of Pharmacy Northeastern University Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics Waltham Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-14"},{"key":"e_1_2_9_3_1","first-page":"60","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski KA","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_9_4_1","first-page":"1779","article-title":"Diagnosis and treatment of\u00a0Neisseria gonorrhoeae\u00a0infections","volume":"73","author":"Miller KE","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_5_1","unstructured":"Sexually Transmitted Disease Surveillance 2013. Available fromhttp:\/\/www.cdc.gov\/std\/stats13\/surv2013-print.pdf. Acce\u2010ssed June 11 2015."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318285c6d2"},{"key":"e_1_2_9_7_1","unstructured":"Cephalosporin\u2010resistant Neisseria gonorrhoeae public health response plan. Available fromhttp:\/\/www.cdc.gov\/std\/treatment\/ceph-r-responseplanjuly30-2012.pdf. Accessed June 11 2015."},{"key":"e_1_2_9_8_1","volume-title":"Sexually transmitted disease surveillance 2012; gonococcal isolates surveillance project (GISP) supplement and profiles","author":"GISP","year":"2014"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04337-14"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2013-051162"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-13"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04476-14"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01295-13"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00788-10"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks162"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku245"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00038-14"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02093-13"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir929"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04456-14"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00083-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.42.3.579","article-title":"The Pazufloxacin STD Group. Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone\u2010resistant isolates with the GyrA mutation","volume":"42","author":"Tanaka M","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"02","key":"e_1_2_9_25_1","first-page":"1","article-title":"Recommendations for the laboratory\u2010based detection of\u00a0Chlamydia trachomatis\u00a0and\u00a0Neisseria gonorrhoeae\u20142014","volume":"63","author":"By P","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92720-9"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199705000-00007"},{"key":"e_1_2_9_28_1","first-page":"1","volume-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization (WHO)","year":"2012"},{"key":"e_1_2_9_29_1","unstructured":"World Health Organization (WHO).Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections. Available fromhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/75729\/1\/9789241504478_eng.pdf. Accessed June 11 2015."},{"key":"e_1_2_9_30_1","unstructured":"The pharmacokinetics of extended duration high\u2010dose cefixime for the decreased susceptibility of Neisseria gonorrhoeae: a phase I pilot study. Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01949363. Accessed June 11 2015."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-006-0445-Z"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04127-14"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt540"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu521"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit084"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-09"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.08.010"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-10"},{"key":"e_1_2_9_39_1","unstructured":"Genitourinary and pharyngeal pharmacokinetics of solithromycin. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02348424. Accessed June 11 2015."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00036-12"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2013-051184.0093"},{"key":"e_1_2_9_42_1","unstructured":"Efficacy and safety study of oral solithromycin compared to intramuscular ceftriaxone plus oral azithromycin in the treatment of patients with gonorrhea (SOLITAIRE\u2010U). Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02210325. Accessed June 11 2015."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03090-14"},{"key":"e_1_2_9_44_1","unstructured":"HossainM TiffanyCA McDonaldM DumontEF.Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944 a novel bacterial topoisomerase inhibitor [abstract]. Presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy: Washington DC 2014."},{"key":"e_1_2_9_45_1","unstructured":"A dose\u2010ranging study evaluating the efficacy safety and tolerability of GSK2140944 in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02294682. Accessed June 11 2015."},{"key":"e_1_2_9_46_1","unstructured":"LawrenceKR O'ConnorKA MuellerJ MathewsD GardnerH.Safety and pharmacokinetics of single escalating oral doses of AZD0914 a novel spiropyrimidinetrione [abstract]. Presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy: Washington DC 2014."},{"key":"e_1_2_9_47_1","unstructured":"Randomized open\u2010label phase 2 study of oral AZD0914 in the treatment of gonorrhea. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02257918. Accessed June 11 2015."},{"key":"e_1_2_9_48_1","unstructured":"Melinta therapeutics ceases phase 3 PROCEEDING study. Available fromhttp:\/\/www.melinta.com\/news.php?c=41. Accessed June 11 2015."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1627","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:35:12Z","timestamp":1761057312000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/phar.1627"],"URL":"https:\/\/doi.org\/10.1002\/phar.1627","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"2015-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}